Scott Matusow Blog | Talkmarkets | Page 1
Team Leader, owner and founder of StockMatusow.com
Contributor's Links: StockMatusow

I'm an independent writer/trader/investor and team leader of StockMatusow.com.

I have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.

I've had the most ... more

Articles

Latest Posts
1 to 16 of 17 Posts
1 2
GlycoMimetics - High Potential Clinical-Stage Biotech
GlycoMimetics is a clinical-stage biotech that we feel has significant potential to be a short, mid, and long term winner. The company has a unique and novel platform in which early data looks very promising.
Calithera Pharma In Focus, Part 3 - Arginase Inhibitor And Acquisition Target
In the last part of our series on Calithera Biosciences we will be examining the company's second clinical asset and its acquisition chances sometime this year or early 2018.
Calithera In Focus, Part 2 - Upcoming Catalysts In TNBC And RCC
In this article, we will review Calithera's upcoming data catalyst value drivers, which should positively effect the company's market capitalization moving forward. Calithera is also poised to eventually become a high value acquisition.
Calithera Pharma In Focus, Part 1 - Checkpoint Inhibition
Clinical stage company Calithera presents an early stage investment opportunity with the ability to enhance therapeutic value to the first wave of IO therapeutics checkpoint inhibitors from Merck's Keytruda and Bristol-Myers Squibb's Opdivo.
Negative Interest Rates Next Up - Will Pump Markets But Eventually Destroy The Global Financial System
In this article, I will go over several key factors concerning future negative interest rates, Quantitative Easing (QE), leverage and liquidity, economic growth and the lack thereof, debt, and my forecast on what to expect moving forward from here.
It's Not Greece Alone - Explaining And Defining Global Finance And The Current Systemic Risk
Many market participants are clearly not understanding the current situation in Greece and the contagion it can cause. It's not Greece alone, its the real systemic contagion risk.
The Fairway Group Long Swing Trade Thesis - Earnings Play/Short Cover
The Fairway Group is set to report on earnings next Tuesday, May 26th, after the bell. Before the last earnings call, the stock made a nice run-up as Fairway has a large short interest due to the past failures of prior management.
Fairway Group Likely To Beat On Bottom Line EPS - Strong Acquisition Candidate
Fairway is scheduled to report earnings from its last quarter May 28. During the last Q the EURO dollar weakened substantially while the dollar gained. Fairway imports a ton of food from Eu Zone. We think for this reason, Fairway will beat on EPS.
MEI Pharma Is Oversold And Will Recover
Recently, MEI Pharma reported that its Phase II trial for Pracinostat in combination with azacitidine failed to meet its primary endpoint. However, Pracinostat has been shown to work in a 2nd line setting. With catalysts upcoming, the stock is oversold and half valued and should rally back.
Institutions Buying MEI Pharma Ahead Of Topline Data Catalyst In Mid-March
MEIP is expecting to release important Phase II topline data next month. We expect to see the stock price continue to increase up until that time. If positive as we expect, the stock should even rally further.
3 Stocks That Should Move Significantly Higher Soon
Today, we list 3 stocks we feel are likely to move higher in the short and midterm.
Activist Shareholder David Callan Pushing For Sale Of Identiv
David Callan is a successful activist shareholder who is pushing for the sale of Identiv, a small company in which Callan holds a substantial position.
Identiv Goes On The Record With Disney Infinity Toys
The company revealed that its NFC technology are in fact part of Disney's Infinity Toys. We include the audio presentation of this a long with the investor slides from the conference.
NFC Adoption By Apple Helps Pave The Way For Identiv
As Near field communications (NFC) gains traction with Apple's new iPhone 6, Identiv (INVE) should benefit from this as the company is well positioned in the segment.
Perceptive Advisors Continues To Buy Amicus, Likely Acquisition Soon
Investor Joseph Edelman leads Perceptive Advisors and since 1999 the fund has returned an annualized 30.2%. Last year, the fund returned about 48%. Edelman works with six biotech analysts to find companies with potential large gains ahead.
Cempra Poised To Join Antibacterial Drug Acquisition Rumor Buzz With Upcoming Data Release
Cempra Pharmaceuticals expects top-line data release for community acquired bacterial pneumonia by the end of Q1'15. With the very recent Tetraphase acquisition rumor buzz, Cempra is certain to join the acquisition buzz fray if its data release proves positive.
1 to 16 of 17 Posts
1 2